Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8053824 | 0.99 | SLC6A2 (0.45) | SLC6A2ALDH1A1CYP2A6CSNK1DMAPK11 | |
| SCHEMBL8038900 | 0.92 | SLC6A2 (0.41) | SLC6A2ALDH1A1CYP2A6MAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL8039092 | 0.91 | SLC6A2 (0.40) | SLC6A2ALDH1A1CYP2A6MAPTMAPK1 | |
| SCHEMBL8056316 | 0.89 | SLC6A2 (0.38) | SLC6A2ALDH1A1CYP2A6CSNK1DMAPK11 | |
| Hydrochloric Acid SCHEMBL8039091 | 0.87 | ALDH1A1 (0.40) | SLC6A2ALDH1A1CYP2A6CSNK1DMAPK11 | |
| SCHEMBL8438931 | 0.86 | CYP2A6 (0.41) | SLC6A2CYP2A6 | |
| SCHEMBL8436369 | 0.86 | SLC6A2 (0.37) | SLC6A2CYP2A6 | |
| SCHEMBL8053584 | 0.83 | SLC6A2 (0.35) | SLC6A2ALDH1A1CSNK1DMAPK11MAPK14 | |
| SCHEMBL8051666 | 0.82 | ALDH1A1 (0.37) | SLC6A2ALDH1A1CYP2A6MAPTHPGD | |
| SCHEMBL7337994 | 0.82 | SLC6A2 (0.34) | SLC6A2ALDH1A1CSNK1DMAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501797-B1 | 3-(SUBSTITUTED AMINO)-1H-INDOLE-2-CARBOXYLIC ACID ESTER AND 3-(SUBSTITUTED AMINO)-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID ESTER DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMA INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. | 2008-06-05 | — | — | US | disclosed |
| EP-1834947-A2 | 3-substituted amino-1H-indole-2-carboxylic acid and 3-substituted amino-benzo[B]thiophene-2carboxylic acid derivatives as interleukin-4 gene expression inhibitors | Aventis Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1501796-B1 | 3-(PYRIDINYL-AMINO)-1H-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMA INC (US) | 2007-05-09 | — | — | EP | disclosed |
| US-7169925-B2 | Indole derivatives as interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1501796-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1501797-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040010029-A1 | Indole derivatives as interleukin -4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-01-15 | — | — | US | disclosed |
| US-20040006123-A1 | Interleukin-4 gene expression inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003091215-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO’ B! THIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS INTERIEUKIN-4 GENE EXPRESSION INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003091214-A1 | 3-SUBSTITUTED AMINO-1H-INDOLE-2-CARBOXYLIC ACID AND 3-SUBSTITUTED AMINO-BENZO | AVENTIS PHARMACEUTICALS INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-6022880-A | Substituted pyridylamino indoles | HOECHST MARION ROUSSEL, INC. (US) | 2000-02-08 | — | — | US | disclosed |
| US-5328920-A | Alleviating memory dysfunctions | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010029-A1 | Indole derivatives as interleukin -4 gene expression inhibitors | IL4, IL4I1, STAT4 | SLC6A2 1344/4885ALDH1A1 1468/4885CYP2A6 1184/4885 |
| US-20040006123-A1 | Interleukin-4 gene expression inhibitors | IL4, STAT4, BCL6 | SLC6A2 2317/4885ALDH1A1 1578/4885CYP2A6 1180/4885 |
| US-20080132481-A1 | INTERLEUKIN-4 GENE EXPRESSION INHIBITORS | IL4, STAT4, STAT6 | SLC6A2 2071/4885ALDH1A1 1900/4885CYP2A6 1159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.